Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Phase II Study OF Goserelin (G) Plus Fulvestrant (F) vs. G Plus Anastrozole (A)vs. G Alone for HR+, Tamoxifen Pretreated, Premenopausal Woman

NCT01266213 is registered in ClinicalTrials.gov with Samsung Medical Center as lead sponsor.

NCT NCT01266213
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01266213 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Phase II Study OF Goserelin (G) Plus Fulvestrant (F) vs. G Plus Anastrozole (A)vs. G Alone for HR+, Tamoxifen Pretreated, Premenopausal Woman
Lead sponsor
Samsung Medical Center
Phase
Phase 2
Overall status
Unknown status
Start date
December 31, 2010
Completion date
December 31, 2019
Enrollment
147 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer nos premenopausal, estrogen receptor positive tumor, metastatic breast cancer